Last Updated: November 16, 2026

Expiring Drug Patents Cheat Sheet
We analyse the patents covering drugs in 134 countries and quickly give you the likely loss-of-exclusivity/generic entry date

➤ Get the Full List

Morocco: These 14 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027

The content of this page is licensed under a Creative Commons Attribution 4.0 International License. Creative Commons License

Preferred citation:
Friedman, Yali, "Morocco: These 14 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027" DrugPatentWatch.com thinkBiotech, 2026 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.
When can ZYKADIA (ceritinib) generic drug versions launch in Morocco?

Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 08, 2026
Generic Entry Controlled by: Morocco Patent 30,923

ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.

See drug price trends for ZYKADIA.

The generic ingredient in ZYKADIA is ceritinib. Additional details are available on the ceritinib profile page.

When can OSENI (alogliptin benzoate; pioglitazone hydrochloride) generic drug versions launch in Morocco?

Generic name: alogliptin benzoate; pioglitazone hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 01, 2027
Generic Entry Controlled by: Morocco Patent 31,169

Drug Price Trends for OSENI
OSENI is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug. There has been litigation on patents covering OSENI

See drug price trends for OSENI.

The generic ingredient in OSENI is alogliptin benzoate; pioglitazone hydrochloride. Additional details are available on the alogliptin benzoate; pioglitazone hydrochloride profile page.

When can XENLETA (lefamulin acetate) generic drug versions launch in Morocco?

Generic name: lefamulin acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 20, 2027
Generic Entry Controlled by: Morocco Patent 31,314
Patent Title: مشتقات بلوروموتيلين لعلاج الأمراض التي تنتقل عن طريق البكتيريا.

XENLETA is a drug marketed by Hong Kong. There are four patents protecting this drug. There has been litigation on patents covering XENLETA

See drug price trends for XENLETA.

The generic ingredient in XENLETA is lefamulin acetate. Additional details are available on the lefamulin acetate profile page.

When can VRAYLAR (cariprazine hydrochloride) generic drug versions launch in Morocco?

Generic name: cariprazine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 11, 2027
Generic Entry Controlled by: Morocco Patent 31,434

Drug Price Trends for VRAYLAR
VRAYLAR is a drug marketed by Abbvie. There are five patents protecting this drug. There has been litigation on patents covering VRAYLAR

See drug price trends for VRAYLAR.

The generic ingredient in VRAYLAR is cariprazine hydrochloride. Additional details are available on the cariprazine hydrochloride profile page.

When can SIGNIFOR LAR (pasireotide pamoate) generic drug versions launch in Morocco?

Generic name: pasireotide pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 24, 2027
Generic Entry Controlled by: Morocco Patent 31,445
Patent Title: COMPOSITION À LIBÉRATION MODIFIÉE COMPRENANT UN DÉRIVÉ DE SOMATOSTATINE EN MICROPARTICULES

SIGNIFOR LAR is a drug marketed by Recordati Rare. There are three patents protecting this drug.

See drug price trends for SIGNIFOR LAR.

The generic ingredient in SIGNIFOR LAR is pasireotide pamoate. Additional details are available on the pasireotide pamoate profile page.

When can TRELSTAR (triptorelin pamoate) generic drug versions launch in Morocco?

Generic name: triptorelin pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2027
Generic Entry Controlled by: Morocco Patent 31,422

TRELSTAR is a drug marketed by Verity. There is one patent protecting this drug.

See drug price trends for TRELSTAR.

The generic ingredient in TRELSTAR is triptorelin pamoate. Additional details are available on the triptorelin pamoate profile page.

When can TRIPTODUR KIT (triptorelin pamoate) generic drug versions launch in Morocco?

Generic name: triptorelin pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2027
Generic Entry Controlled by: Morocco Patent 31,422

TRIPTODUR KIT is a drug marketed by Azurity. There is one patent protecting this drug.

The generic ingredient in TRIPTODUR KIT is triptorelin pamoate. Additional details are available on the triptorelin pamoate profile page.

When can JAKAFI (ruxolitinib phosphate) generic drug versions launch in Morocco?

Generic name: ruxolitinib phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 13, 2027
Generic Entry Controlled by: Morocco Patent 31,517

JAKAFI is a drug marketed by Incyte Corp. There are nineteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering JAKAFI

See drug price trends for JAKAFI.

The generic ingredient in JAKAFI is ruxolitinib phosphate. Additional details are available on the ruxolitinib phosphate profile page.

When can KAZANO (alogliptin benzoate; metformin hydrochloride) generic drug versions launch in Morocco?

Generic name: alogliptin benzoate; metformin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 19, 2027
Generic Entry Controlled by: Morocco Patent 31,592
Patent Title: PREPARATION SOLIDE COMPRENANT L'ALOGLIPTINE ET LE CHLORHYDRATE DE METFORMINE

Drug Price Trends for KAZANO
KAZANO is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering KAZANO

See drug price trends for KAZANO.

The generic ingredient in KAZANO is alogliptin benzoate; metformin hydrochloride. Additional details are available on the alogliptin benzoate; metformin hydrochloride profile page.

When can PROMACTA (eltrombopag olamine) generic drug versions launch in Morocco?

Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 01, 2027
Generic Entry Controlled by: Morocco Patent 30,236

PROMACTA is a drug marketed by Novartis. There is one patent protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. Additional details are available on the eltrombopag olamine profile page.

When can ENTRESTO SPRINKLE (sacubitril; valsartan) generic drug versions launch in Morocco?

Generic name: sacubitril; valsartan
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 02, 2027
Generic Entry Controlled by: Morocco Patent 30,128
Patent Title: COMBINAISONS PHARMACEUTIQUES D'UN ANTAGONISTE DE RECEPTUER D'ANGIOTENSINE ET D'UN INHIBITEUR DE NEP

Drug Price Trends for ENTRESTO SPRINKLE
ENTRESTO SPRINKLE is a drug marketed by Novartis. There are three patents protecting this drug. There has been litigation on patents covering ENTRESTO SPRINKLE

See drug price trends for ENTRESTO SPRINKLE.

The generic ingredient in ENTRESTO SPRINKLE is sacubitril; valsartan. Additional details are available on the sacubitril; valsartan profile page.

When can VELPHORO (sucroferric oxyhydroxide) generic drug versions launch in Morocco?

Generic name: sucroferric oxyhydroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 16, 2027
Generic Entry Controlled by: Morocco Patent 31,898
Patent Title: تراكيب صيدلانية

Drug Price Trends for VELPHORO
VELPHORO is a drug marketed by Vifor Fresenius. There are eleven patents protecting this drug. There has been litigation on patents covering VELPHORO

See drug price trends for VELPHORO.

The generic ingredient in VELPHORO is sucroferric oxyhydroxide. Additional details are available on the sucroferric oxyhydroxide profile page.

When can DUZALLO (allopurinol; lesinurad) generic drug versions launch in Morocco?

Generic name: allopurinol; lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: Morocco Patent 31,936

Drug Price Trends for DUZALLO
DUZALLO is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering DUZALLO

See drug price trends for DUZALLO.

The generic ingredient in DUZALLO is allopurinol; lesinurad. Additional details are available on the allopurinol; lesinurad profile page.

When can ZURAMPIC (lesinurad) generic drug versions launch in Morocco?

Generic name: lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: Morocco Patent 31,936

ZURAMPIC is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering ZURAMPIC

See drug price trends for ZURAMPIC.

The generic ingredient in ZURAMPIC is lesinurad. Additional details are available on the lesinurad profile page.

# Morocco Branded and Generic Drug Market Assessment: Regulatory Opportunities, Patent Risks, and Commercial Outlook

Last updated: October 11, 2026

Morocco has a locally anchored pharmaceutical market with strong generic penetration, regulated pricing, centralized public procurement, and growing demand for chronic-disease medicines. The market offers opportunities for manufacturers that can combine local registration, competitive pricing, supply reliability, and government-tender access. The main constraints are price compression, administrative delays, limited reimbursement budgets, dependence on imported active pharmaceutical ingredients, and a regulatory framework that remains more complex for innovative products, biologics, and advanced therapies.

What is the size and structure of Morocco’s pharmaceutical market?

Morocco’s pharmaceutical market is divided between a regulated private retail channel, public-sector procurement, hospitals, and a smaller export business. Local manufacturers supply most of the country’s finished-dose medicine demand, while imported products remain important in oncology, biologics, specialty medicines, vaccines, orphan drugs, and selected hospital products.

Market characteristic Assessment
Market currency Moroccan dirham, MAD
Main regulator Directorate of Medicines and Pharmacy, Ministry of Health and Social Protection
Domestic manufacturing Strong, with a large base of local finished-dose manufacturers
Generic penetration High in volume, with lower average prices than originator products
Pricing Government-controlled for reimbursed and marketed medicines
Main sales channels Pharmacies, hospitals, public tenders, private clinics, wholesalers
Key commercial issue Access depends on price, reimbursement, distribution and supply continuity
Main growth drivers Universal health coverage, chronic diseases, oncology, diabetes, cardiovascular care and hospital modernization

Industry bodies have estimated the domestic pharmaceutical market at approximately MAD 15 billion in annual sales, although reported totals vary by inclusion of hospital products, vaccines, exports and non-prescription medicines (Association Marocaine de l’Industrie Pharmaceutique, n.d.; IQVIA, 2023).

Morocco’s government has sought to expand pharmaceutical sovereignty through local production, stock requirements and industrial investment. The country has a mature manufacturing base compared with many African markets, but its dependence on imported APIs, excipients, packaging inputs and specialized technologies remains material.

How do branded and generic drugs compare in Morocco?

Generics dominate many primary-care categories, particularly antibiotics, analgesics, antihypertensives, antidiabetics and gastrointestinal products. Branded generics are marketed by Moroccan and multinational companies and compete mainly through price, physician relationships, pharmacy distribution and product availability.

Originator medicines retain stronger positions in:

  • Oncology and immuno-oncology.
  • Biological medicines and specialty injectables.
  • Rare diseases.
  • Innovative hospital products.
  • Products protected by patents or regulatory exclusivity.
  • Brands with strong physician recognition or clinical differentiation.

The distinction between an originator brand and a branded generic is commercially important. A branded generic may have no active patent barrier but can retain market share through local registration, established distribution, prescriber familiarity and procurement relationships.

Generic substitution is not equivalent to automatic pharmacy substitution in every commercial setting. Prescribing practices, reimbursement rules, procurement specifications and physician acceptance affect actual substitution. Companies entering Morocco therefore need a market-access strategy beyond regulatory approval.

What are the main regulatory requirements for marketing authorization?

A medicine requires an authorization to place on the Moroccan market, commonly referred to as an AMM. The process is administered through the Ministry of Health’s Directorate of Medicines and Pharmacy.

The regulatory submission generally requires:

  1. Administrative and legal documentation.
  2. Quality and pharmaceutical development data.
  3. Nonclinical data where applicable.
  4. Clinical or bibliographic evidence.
  5. Stability data.
  6. Manufacturing-site information.
  7. GMP documentation.
  8. Labeling, packaging and French-language product information.
  9. Bioequivalence evidence for relevant generic products.
  10. Pharmacovigilance and post-marketing commitments.

The dossier structure broadly follows internationally recognized technical standards, but local administrative requirements and document legalization can create execution risk. Foreign manufacturers generally need a Moroccan commercial or regulatory representative and must manage local importer, wholesaler and pharmacovigilance obligations.

Morocco is party to the World Trade Organization and has adopted intellectual-property and regulatory practices influenced by international agreements. It is also a member of the African Medicines Agency framework, although the practical effects of regional harmonization remain gradual rather than immediate (World Health Organization, 2022).

How are generic medicines approved in Morocco?

Generic applicants must demonstrate pharmaceutical equivalence and, where required, bioequivalence to the reference product. The regulator may accept reference products authorized in Morocco or recognized foreign jurisdictions, subject to the applicable dossier requirements.

Generic approval opportunities are strongest when:

  • The originator has no enforceable Moroccan patent blocking launch.
  • Regulatory exclusivity has expired or does not apply.
  • Bioequivalence can be demonstrated with a cost-effective study.
  • The product has stable demand in pharmacies or public tenders.
  • The applicant has a reliable local distributor.
  • The dosage form does not require complex manufacturing technology.

Higher regulatory and technical barriers apply to modified-release products, inhalers, transdermal systems, sterile injectables, complex generics and biologics. These products may require more extensive comparative characterization, clinical evidence or manufacturing validation.

What is the regulatory status of biosimilars in Morocco?

Morocco permits the development and registration of biological medicines, including biosimilar products, but biosimilar approval is more demanding than conventional small-molecule generic approval. The applicant must establish similarity in analytical, quality, pharmacokinetic and, where required, clinical terms.

The principal biosimilar opportunities are in:

  • Insulin and other diabetes biologics.
  • Erythropoietins.
  • Filgrastim.
  • Monoclonal antibodies.
  • Oncology biologics.
  • Rheumatology and immunology products.

Market access is constrained by hospital procurement practices, physician confidence, interchangeability expectations and the cost of comparative development. A biosimilar may receive regulatory approval yet face slow uptake if tender specifications favor the reference product or if substitution policies are unclear.

How are medicine prices regulated in Morocco?

Morocco uses a government-controlled pricing system for medicines. The price structure can include a public sale price, wholesale and pharmacy margins, and the manufacturer or importer price. The pricing framework was significantly revised through reforms adopted in the 2010s, with greater emphasis on international price comparison and reducing patient prices.

The commercial effect is substantial:

  • Originator launch prices face external-reference constraints.
  • Generic prices are often required to undercut the reference medicine.
  • Subsequent generic entrants may face additional price reductions.
  • Public tenders emphasize the lowest compliant bid.
  • Reimbursement decisions affect volume and physician prescribing.
  • Price reductions can weaken incentives for low-volume products.

Pricing must be assessed before registration because a technically approvable product may not be commercially viable after mandatory reductions, distribution margins, pharmacovigilance costs and tender discounts.

What patents protect medicines in Morocco?

Moroccan pharmaceutical patents are governed primarily by Law No. 17-97 on the Protection of Industrial Property, as amended, including amendments associated with Law No. 23-13. The standard patent term is generally 20 years from the filing date, subject to statutory conditions and maintenance fees (Moroccan Office of Industrial and Commercial Property, n.d.).

Relevant patent categories include:

  • Active pharmaceutical ingredients.
  • Polymorphs, salts and crystalline forms.
  • Formulations and compositions.
  • Dosage regimens.
  • Manufacturing processes.
  • Combination therapies.
  • Selected medical-use claims, subject to Moroccan patent-law standards.

Morocco does not operate an Orange Book equivalent to the U.S. Food and Drug Administration’s listed-patent system. There is also no direct Moroccan equivalent of the U.S. Paragraph IV certification pathway. Generic applicants must conduct an independent freedom-to-operate analysis using Moroccan patent records, international patent families, prosecution histories and local litigation information.

The absence of an Orange Book-style linkage system can reduce formal patent-linkage delay, but it does not eliminate infringement risk. A patent holder can seek civil remedies, provisional measures or other relief if a commercial launch allegedly infringes a valid Moroccan patent.

When do branded medicines lose exclusivity in Morocco?

Exclusivity depends on four separate dates:

  1. Moroccan patent expiry.
  2. Regulatory data protection expiry, where applicable.
  3. Any supplementary protection or treaty-based protection.
  4. Commercial and reimbursement barriers after generic approval.

The patent expiry date is calculated from the applicable filing date, not from the Moroccan launch date. A late national filing, a national-phase entry date or a separate improvement patent can produce different risk outcomes from the primary international patent family.

The United States-Morocco Free Trade Agreement includes pharmaceutical intellectual-property and regulatory-protection commitments. These provisions can affect reliance on undisclosed test data and market authorization timing, particularly for products containing new chemical entities. The legal effect must be assessed against the product’s filing history and the applicable Moroccan implementation rules (Office of the United States Trade Representative, 2004).

What patent litigation and Paragraph IV risks exist?

Morocco does not have a standardized Paragraph IV litigation process. Generic companies typically manage risk through:

  • Patent searches before dossier submission.
  • Claim-by-claim freedom-to-operate reviews.
  • Assessment of process and formulation patents.
  • Non-infringement or invalidity positions.
  • Launch timing after patent expiry.
  • Negotiated licenses or supply arrangements.
  • Local counsel review of provisional-relief exposure.

Publicly visible pharmaceutical patent litigation is less extensive than in the United States or major European markets. That does not indicate low risk. Local enforcement, importation, manufacturing location and the patent holder’s commercial strategy can determine whether a dispute develops.

A generic manufacturer using an imported API may face risk even when its finished-dose manufacturing is local. The relevant infringement issue can involve the API process, a protected intermediate, a formulation or a manufacturing step.

What manufacturing and intellectual-property barriers affect market entry?

Local manufacturing is commercially valuable but does not remove dependence on imported inputs. Principal barriers include:

  • API availability and supplier qualification.
  • Sterile manufacturing capacity.
  • Cold-chain logistics.
  • Serialization and traceability requirements.
  • Validation of imported manufacturing sites.
  • Technology-transfer controls.
  • Restricted access to reference standards.
  • Complex analytical testing.
  • Capacity constraints in quality-control laboratories.

The government’s local-production agenda creates opportunities for contract manufacturing, technology transfer, local packaging, biosimilar production and public-private supply agreements. Companies that establish Moroccan production or partner with existing manufacturers may improve tender eligibility and supply resilience.

What licensing deals and partnership models are available?

The most practical market-entry models are:

Model Best use case Main risk
Local distributor Conventional imported medicines Limited control over pricing and promotion
Exclusive licensing Branded products and specialty medicines Dependence on partner execution
Contract manufacturing Generics and mature products Quality and capacity-control risk
Technology transfer Strategic local production Upfront investment and IP leakage concerns
Joint venture Large-scale or regulated manufacturing Governance and capital requirements
Local packaging Products with import and logistics advantages Limited value if local-content rules tighten

Licensing is most attractive where the local partner has registration capacity, tender access, pharmacovigilance infrastructure and national distribution. A contract should address ownership of Moroccan registrations, supply interruption, price reductions, audit rights, recalls, variations, trademark control and post-expiry manufacturing rights.

What regulatory opportunities exist for pharmaceutical companies?

The strongest opportunities are linked to public-health priorities and supply gaps.

Chronic-disease medicines

Diabetes, cardiovascular disease, hypertension and respiratory disease provide recurring demand. Generic entrants can compete through low cost, reliable supply and broad pharmacy coverage.

Oncology and specialty medicines

Morocco’s oncology market offers higher-value opportunities but requires reimbursement planning, hospital access and specialist engagement. Biosimilars and supportive-care medicines may have a clearer access path than novel high-cost products.

Local production

Government support for pharmaceutical sovereignty may favor local manufacturing, API initiatives, technology transfer and domestic packaging. Local production can also improve eligibility for public procurement.

Public tenders

Hospitals and public institutions create volume opportunities for injectable medicines, anti-infectives, oncology products, anesthesia, vaccines and chronic-care therapies. Tender pricing can be aggressive, and supply failure can damage future eligibility.

Export platforms

Morocco’s geographic position creates a platform for exports to West Africa and other African markets. Registration in Morocco does not automatically provide access elsewhere, but local GMP capability and regulatory experience can support regional expansion.

What are the principal regulatory and commercial challenges?

The principal challenges are:

  • Approval timelines that can be difficult to forecast.
  • Documentation and legalization requirements.
  • French-language regulatory materials.
  • Controlled and compressed pricing.
  • Public-tender price erosion.
  • Reimbursement limitations.
  • Slow uptake of biosimilars.
  • Dependence on imported APIs.
  • Exposure to currency and freight costs.
  • Limited transparency on patent linkage.
  • Fragmented distribution and prescribing behavior.
  • Working-capital pressure from public-sector payment cycles.

A successful entrant should model net realized price rather than the approved list price. The calculation should include mandatory price reductions, wholesaler and pharmacy margins, rebates, tender discounts, registration costs, pharmacovigilance, local representative fees and inventory requirements.

How does Morocco compare with other North African pharmaceutical markets?

Morocco has a stronger export orientation and a developed private manufacturing base. Algeria has a large public market and substantial local-production policy but more pronounced import restrictions and administrative controls. Tunisia has strong manufacturing and technical capabilities but a smaller domestic market. Egypt offers greater scale but more complex currency, pricing and payment risks.

Morocco is most attractive for companies seeking:

  • A relatively mature regulatory environment.
  • Local manufacturing or packaging.
  • Access to private retail and public procurement.
  • A base for selected African exports.
  • Generic and biosimilar commercialization.

It is less attractive for products that require high prices, rapid reimbursement, unrestricted promotional pricing or minimal local operational presence.

What generic launch scenarios should companies model?

A Moroccan launch assessment should use at least four scenarios:

Scenario Launch condition Commercial result
Early generic entry No blocking patent and rapid approval Fast price erosion, volume competition
Patent-delayed entry Valid formulation or process patent Deferred launch, possible licensing
Tender-led entry Public procurement is the main channel Large volume with low margins
Specialty entry Complex generic or biosimilar Higher barriers, slower substitution, better pricing potential

The highest-risk products are low-volume medicines with complex registration requirements and heavy dependence on imported inputs. The strongest candidates are high-volume chronic therapies with stable demand, manageable bioequivalence requirements and local distribution.

Key Takeaways

  • Morocco has a sizeable, locally manufactured pharmaceutical market with high generic participation.
  • Government pricing and reimbursement controls are central to commercial viability.
  • Local production, public tenders, chronic disease and biosimilars provide the clearest growth opportunities.
  • Morocco has no direct Orange Book or Paragraph IV system, so patent risk requires independent freedom-to-operate analysis.
  • The standard Moroccan patent term is generally 20 years from filing, subject to applicable law and maintenance requirements.
  • Regulatory approval does not guarantee market access; price, reimbursement, procurement and supply continuity determine sales.
  • Local partnerships can improve registration, distribution, tender participation and manufacturing economics.
  • The principal entry risks are price compression, administrative execution, API dependence, payment cycles and limited transparency in patent linkage.

FAQs

Is Morocco a good market for generic drug companies?

Yes. Generic demand is broad, local manufacturing is established, and chronic-disease treatment creates recurring volume. Profitability depends on price approval, reimbursement, distribution and tender strategy.

Can a generic launch in Morocco before patent expiry?

A launch before patent expiry may create infringement exposure if a valid Moroccan patent covers the product, formulation, process or use. Morocco does not provide a U.S.-style Paragraph IV safe harbor.

Does Morocco recognize biosimilars?

Yes. Biosimilar products can be registered, but applicants face greater analytical, clinical, manufacturing and market-access requirements than conventional small-molecule generics.

Are Moroccan medicine prices negotiated or freely set?

Prices are regulated. The approved price and commercial margins are subject to government rules, and public procurement can impose materially lower net prices.

Does Moroccan approval permit sales elsewhere in Africa?

No. Moroccan approval does not automatically authorize sales in other African countries. It can support regional expansion by providing manufacturing, quality and regulatory infrastructure, but each destination generally requires its own authorization.

References

  1. Association Marocaine de l’Industrie Pharmaceutique. (n.d.). The Moroccan pharmaceutical industry and domestic medicine supply. AMIP.

  2. IQVIA. (2023). Morocco pharmaceutical market overview. IQVIA Institute.

  3. Moroccan Office of Industrial and Commercial Property. (n.d.). Industrial property legislation and patent protection in Morocco. OMPIC.

  4. Office of the United States Trade Representative. (2004). United States-Morocco Free Trade Agreement. USTR.

  5. World Health Organization. (2022). WHO global benchmarking tool for evaluation of national regulatory systems. WHO.

More… ↓

⤷  Start Trial

DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more …

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.